Pub Date : 2010-12-01DOI: 10.1097/01.NEP.0000393758.66579.1A
E. Benton
{"title":"Bryan Becker, MD, on 60 Years of the National Kidney Foundation","authors":"E. Benton","doi":"10.1097/01.NEP.0000393758.66579.1A","DOIUrl":"https://doi.org/10.1097/01.NEP.0000393758.66579.1A","url":null,"abstract":"","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"126 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116091371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-12-01DOI: 10.1097/01.NEP.0000393754.74203.7A
L. Szczech
{"title":"Oh What a Year in Nephrology","authors":"L. Szczech","doi":"10.1097/01.NEP.0000393754.74203.7A","DOIUrl":"https://doi.org/10.1097/01.NEP.0000393754.74203.7A","url":null,"abstract":"","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115129664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-12-01DOI: 10.1097/01.NEP.0000393756.58956.FF
M. Hogan
{"title":"Peginesatide As Safe and Efficacious as Epoetin in Trials of Dialysis Patients","authors":"M. Hogan","doi":"10.1097/01.NEP.0000393756.58956.FF","DOIUrl":"https://doi.org/10.1097/01.NEP.0000393756.58956.FF","url":null,"abstract":"","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127736632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-11-01DOI: 10.1097/01.NEP.0000391627.55029.56
M. Hogan
HYATTSVILLE, MD—In patients with chronic kidney disease (CKD) who are not on dialysis, safety signals in trials of erythropoiesis-stimulating agents (ESAs) are cause for caution, but the indication of darbepoetin alfa to treat anemia in this patient group should not be withdrawn, recommended the Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee. At a meeting here in October, the committee members voted 15 to one, plus one abstention, to keep this indication. “I think it’s important to leave some room in the process for autonomy for physician and patient to make the decision as to whether to use it or not,” said Jeffrey Kopp, MD, a temporary voting member of the advisory committee, noting that there are populations who would benefit from this indication. Dr. Kopp is Captain in the US Public Health Service and is affiliated with the Kidney Disease Section of the National Institute of Diabetes and Digestive and Kidney Diseases. The advisory committee met to discuss the results of the Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alfa) Therapy, or TREAT. Like the CHOIR (Correction of Green Light for Existing ESA Label, but Proceed with Caution
{"title":"Green Light for Existing ESA Label, but Proceed with Caution","authors":"M. Hogan","doi":"10.1097/01.NEP.0000391627.55029.56","DOIUrl":"https://doi.org/10.1097/01.NEP.0000391627.55029.56","url":null,"abstract":"HYATTSVILLE, MD—In patients with chronic kidney disease (CKD) who are not on dialysis, safety signals in trials of erythropoiesis-stimulating agents (ESAs) are cause for caution, but the indication of darbepoetin alfa to treat anemia in this patient group should not be withdrawn, recommended the Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee. At a meeting here in October, the committee members voted 15 to one, plus one abstention, to keep this indication. “I think it’s important to leave some room in the process for autonomy for physician and patient to make the decision as to whether to use it or not,” said Jeffrey Kopp, MD, a temporary voting member of the advisory committee, noting that there are populations who would benefit from this indication. Dr. Kopp is Captain in the US Public Health Service and is affiliated with the Kidney Disease Section of the National Institute of Diabetes and Digestive and Kidney Diseases. The advisory committee met to discuss the results of the Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alfa) Therapy, or TREAT. Like the CHOIR (Correction of Green Light for Existing ESA Label, but Proceed with Caution","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115013864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-11-01DOI: 10.1097/01.NEP.0000391633.37103.5B
E. Benton
{"title":"Cleveland Clinic Program Focuses on the Care of the Living Donor","authors":"E. Benton","doi":"10.1097/01.NEP.0000391633.37103.5B","DOIUrl":"https://doi.org/10.1097/01.NEP.0000391633.37103.5B","url":null,"abstract":"","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124111758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-10-01DOI: 10.1097/01.NEP.0000390696.07462.DA
Ajay K. Singh
{"title":"Unraveling Diabetes, One Gene at a Time","authors":"Ajay K. Singh","doi":"10.1097/01.NEP.0000390696.07462.DA","DOIUrl":"https://doi.org/10.1097/01.NEP.0000390696.07462.DA","url":null,"abstract":"","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126676951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：